News

A Phase 2a clinical trial investigating Woolsey Pharmaceuticals‘ oral treatment Bravyl in people with amyotrophic lateral sclerosis (ALS) has dosed the first patient in the high-dose group, kicking off the next stage of the study. The REAL clinical trial (NTC05218668) already showed signs of slower disease progression…

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech, has developed a comprehensive resource designed to help people with amyotrophic lateral sclerosis (ALS) find ongoing clinical trials applicable to their condition and location. Dubbed the ALS Trial Navigator, the new tool uses mapping technology from Esri,…

New research into the molecular underpinnings of amyotrophic lateral sclerosis (ALS) has uncovered sex differences and disease subtypes, which could inform the development of new and more targeted treatment strategies. Comprehensive analyses of ALS brain tissue samples and mouse models also identified the MAPK/ERK cell signaling pathway as a possible…

Elevated blood levels of neurofilament light chain (NfL), a biomarker of nerve cell damage, are linked to faster disease progression and shorter survival in most people with amyotrophic lateral sclerosis (ALS), a new study found. However, the team of researchers observed that blood NfL levels among patients differed by…

Men who are more active and physically fit have lower long-term risk of developing amyotrophic lateral sclerosis (ALS), according to findings from a large Norwegian study. No such link was observed in female patients, for reasons that are not entirely clear. The results may counter a concern that higher…

Biotechnology company ProJenX has received a $1 million grant from the ALS Association to support a portion of an ongoing clinical trial, which will test prosetin in people with amyotrophic lateral sclerosis (ALS). The PRO-101 Phase 1 trial (NCT05279755) is testing prosetin in three parts. The…

Amyotrophic lateral sclerosis (ALS) patients who used NeuroSense Therapeutics‘ investigational therapy PrimeC for a year saw significantly slower disease progression and prolonged survival relative to patients who started the treatment six months later. That’s according to one-year findings from the PARADIGM Phase 2b clinical trial (NCT05357950),…

An advisory committee of the European Medicines Agency (EMA) has recommended against granting conditional marketing authorization to masitinib as an oral add-on treatment for amyotrophic lateral sclerosis (ALS). The negative opinion by the Committee for Medicinal Products for Human Use (CHMP) confirms the committee’s view, announced last…

BrainStorm Cell Therapeutics has reached an alignment with the U.S. Food and Drug Administration (FDA) on the chemistry, manufacturing, and controls aspects — known as CMC — of the company’s upcoming Phase 3b trial of NurOwn (debamestrocel), to be tested in people with amyotrophic lateral sclerosis (ALS). This…

In amyotrophic lateral sclerosis (ALS), nerve cells in the spinal cord responsible for inhibiting motor neurons are lost in the early stages of the disease, before the motor neurons themselves, according to a new study done in a genetic mouse model of ALS. The researchers also found that excitatory…